BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia

2010 ◽  
Vol 25 (6) ◽  
pp. 311-313 ◽  
Author(s):  
G. Spalletta ◽  
D.W. Morris ◽  
F. Angelucci ◽  
I.A. Rubino ◽  
I. Spoletini ◽  
...  
Keyword(s):  
Aggressive Behavior ◽  
Neurotrophic Factor ◽  
Aggressive Behaviour ◽  
Brain Derived Neurotrophic Factor ◽  
Gene Variants ◽  
Bdnf Gene ◽  
Val66met Polymorphism ◽  
Schizophrenic Patients ◽  
Bdnf Val66met Polymorphism ◽  
The Relationship

AbstractBrain-derived neurotrophic factor (BDNF) gene variants may potentially influence behaviour. In order to test this hypothesis, we investigated the relationship between BDNF Val66Met polymorphism and aggressive behaviour in a population of schizophrenic patients. Our results showed that increased number of BDNF Met alleles was associated with increased aggressive behaviour.

scholarly journals The genetic influence of the brain-derived neurotrophic factor Val66Met polymorphism in chronic low back pain

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Angela Shiratsu Yamada ◽  
Flavia Tasmim Techera Antunes ◽  
Camila Ferraz ◽  
Alessandra Hubner de Souza ◽  
Daniel Simon
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Neurotrophic Factor ◽  
Central Sensitization ◽  
Low Back ◽  
Bdnf Gene ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism ◽  
The Brain

Abstract Background The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP). Methods A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism. Results The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP. Conclusion The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

scholarly journals Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Li He ◽  
Yanhui Liao ◽  
Qiuxia Wu ◽  
Tieqiao Liu
Keyword(s):  
Neurotrophic Factor ◽  
Meta Analysis ◽  
Brain Derived Neurotrophic Factor ◽  
Current Data ◽  
Cochrane Library ◽  
Case Control Studies ◽  
Val66met Polymorphism ◽  
Asian Populations ◽  
Bdnf Val66met Polymorphism ◽  
Relationship Of

Background: Several studies had examined the association between brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and methamphetamine (METH) use disorder, whereas the results were conflicting. The aim of this study was to conduct a meta-analysis to achieve a pooled effect size of the association between BDNF Val66Met polymorphism and METH use disorder.Methods: Literature searches were conducted in PubMed, EMBASE, and Cochrane Library up to July, 2020. All relevant studies on the relationship of BDNF Val66Met polymorphism and METH addiction were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated in the dominant, recessive, co-dominant, and allele model to appraise the association.Results: Seven case–control studies with a total of 2,204 subjects (956 METH-dependent cases and 1,248 healthy controls) were included in this meta-analysis. The results showed a significant correlation between BDNF Val66Met polymorphism and METH dependence in overall population under different genetic models. However, subgroup analysis indicated that the association only existed in Han Chinese but not in other Asian populations.Conclusion: Although the current data indicate that BDNF Val66Met polymorphism might be a potential genetic factor for METH use disorder, more researches are needed to prove its role in different populations.

Brain-derived neurotrophic factor and electroconvulsive therapy in a schizoaffective patient with treatment-resistant paranoid-hallucinatory symptoms

2011 ◽  
Vol 26 (S2) ◽  
pp. 1148-1148
Author(s):  
G. Martinotti ◽  
V. Ricci ◽  
M. Di Nicola ◽  
C. Caltagirone ◽  
P. Bria ◽  
...  
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Neurotrophic Factor ◽  
Poor Response ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Treatment Resistant ◽  
Schizophrenic Patients ◽  
General Improvement ◽  
The Relationship

It has been proposed that deficits in the production and the utilization of brain-derived neurotrophic factor (BDNF) may contribute to the pathogenesis of schizophrenia. At the same time, electroconvulsive therapy (ECT) has been shown to induce a robust increase of BDNF protein in animal models. These findings suggest that one putative mechanism of action of ECT is the regulation of BDNF and/or related neurotrophins. In this case report a 54-year-old man with severe treatment-resistant schizophrenic symptoms was treated with ECT. In order to evaluate the effect of ECT on BDNF serum levels, we collected a blood sample before each ECT session. During the course of ECT treatment the paranoid and hallucinatory symptoms gradually improved while BDNF levels increased over time. In addition, there was a general improvement of its positive and negative schizophrenic symptoms and depressive state.In conclusion, this case report further validates the therapeutic efficacy of ECT in schizophrenic patients with inadequate or poor response to traditional treatments. Moreover, ECT therapeutic effect is associated with an increase in BDNF serum levels. Further studies are needed to characterize the relationship between BDNF and ECT in patients with schizophrenia symptoms.

scholarly journals The brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism affects memory performance in older adults

2017 ◽  
Vol 39 (2) ◽  
pp. 90-94 ◽  
Author(s):  
Lucas A. de Azeredo ◽  
Tatiana De Nardi ◽  
Mateus L. Levandowski ◽  
Saulo G. Tractenberg ◽  
Julia Kommers-Molina ◽  
...  
Keyword(s):  
Older Adults ◽  
Neurotrophic Factor ◽  
Memory Performance ◽  
Brain Derived Neurotrophic Factor ◽  
Bdnf Gene ◽  
Val66met Polymorphism ◽  
The Brain
Sign in / Sign up

Export Citation Format

Share Document